Esperion Therapeutics ESPR Accumulated Depreciation
Accumulated Depreciation at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment.
The official record: Esperion Therapeutics’s 10-K, filed March 10, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's accumulated depreciation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's accumulated depreciation?
- Esperion Therapeutics (ESPR) reported accumulated depreciation of $2.18M in Q4 2025.
- How has Esperion Therapeutics's accumulated depreciation changed year-over-year?
- Esperion Therapeutics's accumulated depreciation increased by 5.1% year-over-year, from $2.07M to $2.18M.
- What is the long-term trend for Esperion Therapeutics's accumulated depreciation?
- Over 5 years (2020 to 2025), Esperion Therapeutics's accumulated depreciation has grown at a 6.8% compound annual growth rate (CAGR), from $1.57M to $2.18M.
- What does accumulated depreciation mean?
- Total accumulated depreciation on property, plant, and equipment since acquisition — represents the consumed portion of asset useful lives.